Skip to content

Neurocrine Biosciences NBIX Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
XER
Xeris Biopharma Holdings, Inc.XERS

Other financials

Income statement

See full
Revenue$814.5M+42.2%
Gross profit$800.7M+42.1%
Operating income$193.4M+719%
Net income$197.9M+2,405%
EPS (diluted)$1.91+2,287%

Balance sheet

See full
Cash & equivalents$274.5M+35.8%
Total debt$463.5M-6.0%
Total equity$3.4B+34.4%
Total assets$4.9B+33.0%

Cash flow

See full
Operating cash flow$145.8M+125%
CapEx$9.1M-15.0%
Free cash flow$136.7M+153%

Valuation

See full
Market cap$17.74B+38.4%
Enterprise value$17.93B+37.6%
P/E26.5×-10.3×
P/S5.7×+0.6×

Profitability

See full
Gross margin98.2%-0.3pp
Operating margin25.4%+4.9pp
Net margin21.6%+8.9pp
FCF margin26.8%+6.4pp

Returns & leverage

See full
Return on equity22.5%+10.1pp
Debt / equity0.1×-0.1×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Neurocrine Biosciences in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neurocrine Biosciences's amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neurocrine Biosciences's amortization of capitalized software and acquired intangible assets?
Neurocrine Biosciences (NBIX) reported amortization of capitalized software and acquired intangible assets of $100K in Q1 2026.
How has Neurocrine Biosciences's amortization of capitalized software and acquired intangible assets changed year-over-year?
Neurocrine Biosciences's amortization of capitalized software and acquired intangible assets decreased by 90.0% year-over-year, from $1M to $100K.